Clinical Outcomes in Patients with Waldenstrom Macroglobulinemia (WM) Receiving Ibrutinib on the Phase 3 ASPEN Study=1 Year After Transitioning to ZanubrutinibRamon Garcia-Sanz,Roger Owen,Wojciech Jurczak,Meletios A. Dimopoulos,Helen McCarthy,Gavin Cull,Stephen Opat,Jorge J. Castillo,Marie Jose Kersten,Bjorn E. Wahlin,Sebastian Grosicki,Radha Prathikanti,Tian Tian,Heather Allewelt,Aileen Cleary Cohen,Constantine S. TamBLOOD（2023）引用 0|浏览2暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
